While pregnancy and having a baby can bring lots of joy, it is estimated that one in nine women in the United States experiences postpartum depression. There’s a new treatment drug for this that has recently been approved. It is known as brexanolone. The new drug is expected to help women everywhere deal with this common condition. This is exciting news because the drug is the first of its kind in the United States developed specifically for treating postpartum depression.
A Possible Solution for Millions
Postpartum depression is a period of physical, emotional, and behavioral changes after childbirth that can last for a few months. Brexanolone works by stimulating a natural steroid. This goes on to alleviate the symptoms of postpartum depression. The symptoms of the condition include anxiety, sadness, hopelessness, and difficulty bonding with the newborn.
The FDA approved brexanolone or Zulpresso, its marketing name, on the 19th of March this year. By June, the drug is expected to be available to the public. Sage Therapeutics, which is based in Massachusetts, is the company behind the development of this new remedy that could potentially help around 11 million women in the country.
The cost of the new drug is not low. The intensive treatment is expected to cost between $20,000 and $35,000. This must be administered as an intravenous drip running for 60 hours in a hospital. So far, the price and treatment method are clouding some of the excitement about the drug, but women who went through the clinical trials have expressed that the two-and-a-half days of treatment were certainly worth It considering the relief they felt afterward.
Sage Therapeutics is continuing their research and development efforts. They are currently working on a pill version of the treatment. It is hoped that the new drug is going to be covered by insurance to make it more accessible.